JP Morgan Chase
NBIX icon

JP Morgan Chase’s Neurocrine Biosciences NBIX Stock Holding History

JP Morgan Chase’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.84M Sell
52,000
-29,000
-36% -$4.3M ﹤0.01% 2916
2026
Q1 		$10.4M Buy
81,000
+51,000
+170% +$6.77M ﹤0.01% 2632
2025
Q4 		$4.25M Buy
+30,000
New +$4.35M ﹤0.01% 3471
2025
Q2 		– Sell
-57,000
Closed -$6.3M – 7451
2025
Q1 		$6.3M Hold
57,000
– – ﹤0.01% 2955
2024
Q4 		$7.78M Buy
57,000
+22,000
+63% +$2.72M ﹤0.01% 2941
2024
Q3 		$4.03M Buy
35,000
+5,000
+17% +$685K ﹤0.01% 3373
2024
Q2 		$4.13M Buy
+30,000
New +$4.11M ﹤0.01% 3177
2021
Q3 		– Sell
-25,000
Closed -$2.43M – 6682
2021
Q2 		$2.43M Hold
25,000
– – ﹤0.01% 3655
2021
Q1 		$2.43M Sell
25,000
-16,800
-40% -$1.76M ﹤0.01% 3568
2020
Q4 		$4.01M Buy
+41,800
New +$4.04M ﹤0.01% 2991
2019
Q2 		– Sell
-257,100
Closed -$22.7M – 5915
2019
Q1 		$22.7M Buy
257,100
+212,100
+471% +$17.7M ﹤0.01% 1457
2018
Q4 		$3.21M Buy
+45,000
New +$4.31M ﹤0.01% 2914
2018
Q2 		– Sell
-30,000
Closed -$2.49M – 5629
2018
Q1 		$2.49M Buy
+30,000
New +$2.53M ﹤0.01% 3106
2016
Q3 		– Sell
-32,800
Closed -$1.49M – 4707
2016
Q2 		$1.49M Buy
32,800
+17,800
+119% +$820K ﹤0.01% 2964
2016
Q1 		$593K Buy
+15,000
New +$595K ﹤0.01% 3290

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

JP Morgan Chase's NBIX Position: Q2 2026 in Review

JP Morgan Chase increased its Neurocrine Biosciences (NBIX) stake by 18% in Q2 2026, buying an estimated $142M and bringing the position to 6,398,674 shares worth $1.09B. The position accounts for 0.06% of the portfolio, ranked #258.

JP Morgan Chase first reported a position in NBIX in Q2 2013 and has held it in 51 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • JP Morgan Chase held 6,398,674 shares of Neurocrine Biosciences worth $1.09B as of Q2 2026.
  • JP Morgan Chase bought 956,607 Neurocrine Biosciences shares in Q2 2026, an estimated $142M.
  • Neurocrine Biosciences made up 0.06% of JP Morgan Chase's portfolio in Q2 2026, its #258 holding.
  • JP Morgan Chase first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 51 quarters since.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.